Palvella Therapeutics (PVLA) Other Working Capital Changes (2014 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Other Working Capital Changes of -$49000.0 for Q1 2026.
Palvella Therapeutics (PVLA) Other Working Capital Changes (2014 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Other Working Capital Changes for 13 consecutive years, with $357000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 143.59% year-over-year to $357000.0; the TTM figure through Mar 2026 stood at -$188000.0 (down 125.47% YoY), while the FY2025 annual figure was -$1.4 million, down 190.75% from the prior year.
- Other Working Capital Changes held at -$49000.0 in Q1 2026 per PVLA's latest filing.
- Across five years, Other Working Capital Changes topped out at $19.7 million in Q1 2022 and bottomed at -$47.6 million in Q4 2022.
- Historically, Other Working Capital Changes has averaged -$1.2 million across 5 years, with a median of $134000.0 in 2024.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes surged 3341.02% — and 2025, when it sank 1416.67%.
- Palvella Therapeutics' Other Working Capital Changes stood at -$47.6 million in 2022, then rose by 28.37% to -$34.1 million in 2023, then soared by 103.7% to $1.3 million in 2024, then plunged by 117.62% to -$222000.0 in 2025, then soared by 260.81% to $357000.0 in 2026.
- Business Quant data shows PVLA's Other Working Capital Changes at $357000.0 in Q1 2026, -$222000.0 in Q4 2025, and -$182000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.07 Mn |
| Jun 30, 2026 | 1.07 Mn |
| Jun 30, 2026 | 1.07 Mn |
| Mar 31, 2026 | 357,000.00 |
| Mar 31, 2026 | 357,000.00 |
| Mar 31, 2026 | 357,000.00 |
| Dec 31, 2025 | -222,000.00 |
| Dec 31, 2025 | -222,000.00 |
| Dec 31, 2025 | -222,000.00 |
| Sep 30, 2025 | -182,000.00 |
| Sep 30, 2025 | -182,000.00 |
| Sep 30, 2025 | -182,000.00 |
| Jun 30, 2025 | -141,000.00 |
| Jun 30, 2025 | -141,000.00 |
| Jun 30, 2025 | -141,000.00 |
| Mar 31, 2025 | -819,000.00 |
| Mar 31, 2025 | -819,000.00 |
| Mar 31, 2025 | -819,000.00 |
| Dec 31, 2024 | 1.26 Mn |
| Dec 31, 2024 | 1.26 Mn |